Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Stock Short Interest Declines 93.2%

Posted by Stanley Muller on Oct 9th, 2026

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totaling 18,380 shares, a decrease of 93.2% from the September 15th total of 271,866 shares. Based on an average daily trading volume, of 722,370 shares, the days-to-cover ratio is currently 0.0 days. Currently, 1.8% of the company’s shares are sold short.

Biodexa Pharmaceuticals Stock Down 12.1%

NASDAQ:BDRX traded down $0.06 during trading hours on Friday, hitting $0.46. 156,849 shares of the company’s stock traded hands, compared to its average volume of 1,507,578. Biodexa Pharmaceuticals has a twelve month low of $0.45 and a twelve month high of $52.05. The stock’s fifty day moving average price is $1.01 and its two-hundred day moving average price is $2.36.

Hedge Funds Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for approximately 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, September 28th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Get Our Latest Analysis on Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Company Profile

(Get Free Report)

Biodexa Pharmaceuticals plc, formerly known as Midatech Pharma plc, is a biopharmaceutical company focused on developing medicines for diseases with significant unmet medical needs. The company’s work has centered on oncology, rare diseases and conditions that are difficult to treat with conventional drug-delivery methods.

Biodexa’s development programs have included MTX110, a proprietary aqueous formulation of panobinostat being investigated for direct administration into brain tumors, including diffuse intrinsic pontine glioma.